Geode Capital Management, LLC Lantern Pharma Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 87,435 shares of LTRN stock, worth $253,561. This represents 0.0% of its overall portfolio holdings.

Number of Shares

87,435

Previous 86,347 1.26%

Holding current value

$253,561

Previous $403,000 20.6%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.42 - $4.83 $3,720 - $5,255	1,088 Added 1.26%	87,435 $320,000
Q2 2024 Aug 09, 2024	SELL	$3.91 - $9.51 $4,015 - $9,766	-1,027 Reduced 1.18%	86,347 $403,000
Q1 2024 May 13, 2024	SELL	$3.73 - $10.65 $28,579 - $81,600	-7,662 Reduced 8.06%	87,374 $768,000
Q3 2023 Nov 13, 2023	BUY	$3.41 - $5.51 $17,084 - $27,605	5,010 Added 5.57%	95,036 $324,000
Q2 2023 Aug 11, 2023	BUY	$4.56 - $6.02 $147,069 - $194,157	32,252 Added 55.82%	90,026 $507,000
Q4 2022 Feb 13, 2023	SELL	$4.19 - $6.04 $565 - $815	-135 Reduced 0.23%	57,774 $348,000
Q3 2022 Nov 14, 2022	BUY	$4.59 - $6.5 $1,583 - $2,242	345 Added 0.6%	57,909 $276,000
Q2 2022 Aug 12, 2022	BUY	$4.82 - $7.45 $2,511 - $3,881	521 Added 0.91%	57,564 $328,000
Q3 2021 Nov 12, 2021	BUY	$10.53 - $14.93 $16,468 - $23,350	1,564 Added 2.82%	57,043 $637,000
Q2 2021 Aug 13, 2021	BUY	$12.94 - $19.89 $124,858 - $191,918	9,649 Added 21.05%	55,479 $809,000
Q1 2021 May 12, 2021	BUY	$14.34 - $21.92 $657,202 - $1 Million	45,830 New	45,830 $831,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.31M

Call Options Held

39.8K

Put Options Held

6.1K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $31.4M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Lantern Pharma Inc. Transaction History